Our Oncology Clinical Strategy is designed to transform survival

Use a maximum of two downloads here

Home / Our therapy areas / Oncology / Clinical Strategy

At AstraZeneca, we think differently about the underlying genetic causes of cancer. Our clinical strategy aims to transform survival by seeking to combat metastatic and resistant disease and providing options to treat early. We are defining new biomarkers and therapeutic targets that cut across multiple tumour types. We are transforming the way people with cancer are diagnosed and treated by looking in new places, beyond traditional classifications and focusing on the properties of a tumour, not just its type.

Introduction to our clinical strategy

Our clinical stratgy is designed to transform survival. We aim to combat cancer at all stages, but we know that the earlier we can detect and address cancer, the closer we may be to better outcomes.

Trending stories

Latest Oncology News

Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial
  • Corporate Press Release
Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers
  • Corporate Press Release
Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
  • Corporate Press Release
AstraZeneca advances haematology and cell therapy ambition with largest-ever presence at ASH
  • Corporate Press Release
Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
  • Corporate Press Release
Enhertu reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
  • Corporate Press Release
View all news and press releases

Explore our Oncology pillars

Medicines: Portfolio and Pipeline

With our portfolio, our pipeline and our people, we aim to revolutionise cancer care.

Patient Experience

We are catalysing changes in the practice of medicine to transform the patient experience.

Our People & Culture

Our people, passion and innovation drive us.